View Older Stories View More Recent Stories

Jan 12, 2026 06:30PM AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
Jan 12, 2026 07:30AM AbbVie licenses cancer drug from RemeGen for $650 million upfront
Jan 12, 2026 07:30AM AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
Jan 12, 2026 06:00AM AbbVie to acquire West Pharmaceutical facility in Arizona for $175M
Jan 12, 2026 06:00AM AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
Jan 7, 2026 08:00AM AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
Jan 5, 2026 08:00AM AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
Dec 2, 2025 08:15AM AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Nov 24, 2025 08:00AM AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
Nov 18, 2025 12:48PM AbbVie receives FDA approval for EPKINLY combination therapy for lymphoma
Nov 18, 2025 12:47PM AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
Nov 14, 2025 12:30PM AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
Nov 13, 2025 08:30AM AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
Nov 12, 2025 08:30AM Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
Oct 31, 2025 07:49AM AbbVie Reports Third-Quarter 2025 Financial Results
Oct 29, 2025 05:00PM The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
Oct 29, 2025 08:11AM AbbVie's upadacitinib meets vitiligo study endpoints
Oct 29, 2025 08:11AM AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
Oct 28, 2025 09:00AM Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
Oct 21, 2025 08:00AM The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
Oct 20, 2025 08:00AM AbbVie's RINVOQ outperforms HUMIRA in rheumatoid arthritis study
Oct 20, 2025 08:00AM RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
Oct 17, 2025 09:00AM AbbVie completes acquisition of Gilgamesh's depression drug bretisilocin
Oct 17, 2025 09:00AM AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
Oct 13, 2025 10:58AM FDA approves expanded RINVOQ indication for inflammatory bowel disease
Oct 13, 2025 10:57AM U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
Oct 13, 2025 07:15AM AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
Oct 9, 2025 08:00AM SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
Oct 6, 2025 09:02AM AbbVie's Botox meets primary endpoint in essential tremor trial
Oct 6, 2025 09:00AM AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
Oct 2, 2025 08:00AM AbbVie to Host Third-Quarter 2025 Earnings Conference Call
Sep 30, 2025 03:02PM AbbVie starts $70 million expansion at Massachusetts biologics facility
Sep 30, 2025 03:00PM AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
Sep 30, 2025 08:01AM AbbVie submits FDA application for rare blood cancer treatment
Sep 30, 2025 08:00AM AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
Sep 29, 2025 12:01PM AbbVie breaks ground on $195 million Illinois manufacturing facility
Sep 29, 2025 12:00PM AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
Sep 29, 2025 09:01AM AbbVie sets UK price for ovarian cancer drug ELAHERE equal to US rate
Sep 29, 2025 09:00AM AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
Sep 26, 2025 08:45AM AbbVie submits FDA application for parkinson's drug tavapadon
Sep 26, 2025 08:45AM AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
Sep 9, 2025 08:00AM BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
Sep 5, 2025 09:07AM AbbVie Declares Quarterly Dividend
Sep 3, 2025 08:30AM AbbVie reports outpatient monitoring results for lymphoma drug
Sep 3, 2025 08:30AM AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lym
Sep 3, 2025 08:00AM Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers
Sep 2, 2025 08:00AM AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 25, 2025 08:59AM AbbVie to acquire depression therapy from Gilgamesh for up to $1.2 billion
Aug 25, 2025 08:59AM AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
Aug 21, 2025 08:30AM AbbVie reports positive phase 3 trial results for alopecia areata drug
View More Recent Stories View Older Stories